Skip to main content
SpringerLink
Log in

Dipeptidylpeptidase-4-Inhibitoren (Gliptine) geraten in den Fokus

Coming into focus: dipeptidyl peptidase 4 inhibitors (gliptins)

  • Journal Club
  • Published:
Der Hautarzt Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Röhrborn D, Wronkowitz N, Eckel J (2015) DPP4 in diabetes. Front Immunol 6:386

    Article  Google Scholar 

  2. Jedlowski PM, Te CH, Segal RJ, Fazel MT (2019) Cutaneous adverse effects of diabetes mellitus medications and medical devices: A review. Am J Clin Dermatol 20:97–114

    Article  Google Scholar 

  3. Langan SM, Groves RW, West J (2011) The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 131:631–636

    Article  CAS  Google Scholar 

  4. Kridin K, Ludwig RJ (2018) The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. Front Med 5:220

    Article  Google Scholar 

  5. Gaudin O, Seta V, Alexandre M, Bohelay G, Aucouturier F, Mignot-Grootenboer S, Ingen-Housz-Oro S, Bernardeschi C, Schneider P, Mellottee B, Caux F, Prost-Squarcioni C (2018) Gliptin accountability in mucous membrane pemphigoid induction in 24 out of 313 patients. Front Immunol 9:1030

    Article  Google Scholar 

  6. Gravani A, Gaitanis G, Tsironi T, Tigas S, Bassukas ID (2018) Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.14957

    Article  PubMed  Google Scholar 

  7. Varpuluoma O, Försti AK, Jokelainen J et al (2018) Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case-control study. J Amacad Dermatol 79:1034–1038

    Article  CAS  Google Scholar 

  8. Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, Feldmeyer L (2018) Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol 78:1090–1096

    Article  CAS  Google Scholar 

  9. https://online.rote-liste.de/. Zugegriffen: 4. März 2019

  10. Chijiwa C, Takeoka S, Kamata M, Tateishi M, Fukaya S, Hayashi K et al (2018) Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid. J Dermatol 45:596–599

    Article  CAS  Google Scholar 

  11. Sachs B, Meier T, Nöthen MM, Stieber C, Stingl J (2018) Arzneimittelinduzierte Angioödeme: Bradykinin im Fokus. Hautarzt 69:298–305

    Article  CAS  Google Scholar 

  12. Liu R, Cheng J, Wu H (2019) Discovery of food-derived dipeptidyl peptidase IV inhibitory peptides: a review. Int J Mol Sci 20:463

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Allergologie und Venerologie, Comprehensive Allergy Center (CAC), Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Bettina Wedi

Authors
  1. Bettina Wedi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bettina Wedi.

Ethics declarations

Interessenkonflikt

B. Wedi erhielt in den letzten 3 Jahren Vortragshonorare bzw. Honorare für Advisory Boards der Firmen ALK-Abelló, Astellas, Celgene, Dr. Pfleger, HAL Allergy, Novartis, Shire und eine Forschungsunterstützung der Firma Shire.

Additional information

Redaktion

J. Krutmann, Düsseldorf

Redaktionelle Mitarbeit

R. Gläser, Kiel

B. Homey, Düsseldorf

E. Makrantonaki, Ulm

B. Wedi, Hannover

A.S. Yazdi, Aachen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wedi, B. Dipeptidylpeptidase-4-Inhibitoren (Gliptine) geraten in den Fokus. Hautarzt 70, 388–391 (2019). https://doi.org/10.1007/s00105-019-4400-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-019-4400-1

Search

Navigation